A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Completed · Phase 2, Phase 3 · NCT02819635
Conditions: Ulcerative Colitis (UC)
At a glance
- Research payments reported, 2025
- $9,675
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,302
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo (drug), Upadacitinib (drug)
- Dates
- Started 2016-09-26; completion 2021-12-13
- Results posted
- Yes
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.
From ClinicalTrials.gov, last updated 2022-06-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,675 in research payments for this study in 2025 (1 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Advanced Research Institute Inc $9,675
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.